Fenwick & West LLP represented Dermira, Inc., a development-stage, private company centered on developing and commercializing innovative new therapies in dermatology, in its recently announced investment of $42 million in a Series A financing. The transaction investors were Bay City Capital, New Enterprise Associates, and Canaan Partners. This round of funding will be used to support the acquisition, development and commercialization of novel therapeutics in dermatology.
The Fenwick transaction team was led by corporate partners Douglas Cogen and David Michaels and corporate associates Michael Brown, Ran Ben-Tzur and Sheri Wardwell; and technology transactions partner Lisa Kenkel and technology transactions associate Lance Stern.
Fenwick & West provides comprehensive legal services to more than 500 venture-backed technology and life sciences clients, and has strong connections to technology and life sciences investors across the U.S. who invest at all stages. Fenwick is committed to providing innovative, cost-effective and practical legal services that help emerging companies gain competitive advantages. We differentiate ourselves by having a deep understanding of our clients' technologies, industry environments and business needs. We also receive praise for our innovative use of technology, our pro bono work and diversity efforts.